# Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia

> **NCT04289220** · PHASE1 · UNKNOWN · sponsor: **Yan'an Affiliated Hospital of Kunming Medical University** · enrollment: 10 (estimated)

## Conditions studied

- B Cell Lymphoma
- B-cell Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** Anti-CD19 CAR-T Cells Injection

## Key facts

- **NCT ID:** NCT04289220
- **Lead sponsor:** Yan'an Affiliated Hospital of Kunming Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-15
- **Primary completion:** 2023-03-15
- **Final completion:** 2023-09-15
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2021-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04289220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04289220, "Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04289220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*